Impact Of Inclisiran on Major Adverse Cardiovascular Events in Participants with Established Cardiovascular Disease (VICTORION-2 PREVENT)

Go Back to All Clinical Trials

Impact Of Inclisiran on Major Adverse Cardiovascular Events in Participants with Established Cardiovascular Disease (VICTORION-2 PREVENT)

Brief description of study

The purpose of this research study is to determine if the study treatment, an FDA approved drug known to be safe and effective in lowering bad cholesterol called inclisiran, taken in addition to a statin medication used to treat people with established cardiovascular disease, can safely and effectively lower the risk of cardiovascular events in the future (such as or including heart attacks, strokes, and cardiovascular-related deaths).

Clinical Study Identifier: s22-00135

ClinicalTrials.gov Identifier: NCT05030428

Principal Investigator: Todd C Kerwin.

Other Investigators: Joshua R Deleon, Cirous Sadeghi, Barbara J George.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies